Salmonella vector (L-12259) .: NR16-176/2017E-PDF
“Promising approaches for delivering antigens and generating a protective response against cancers and infectious diseases currently employ existing vaccine strain bacteria or closely-related attenuated bacteria. Human clinical trials have shown excellent safety profiles with various recombinant vaccine strain bacteria, but generally poor efficacies for promoting immunity against the targeted diseases. Finding the right vaccine vector and antigen production system to rapidly induce an immune response while causing minimal toxicity has been challenging. To address this problem, the NRC has developed a recombinant attenuated Salmonella vaccine system capable of producing rapid cell-mediated immune protection against infectious diseases and cancers”--Highlights.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.847591&sl=0
| Department/Agency | National Research Council Canada. |
|---|---|
| Title | Salmonella vector (L-12259) . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Vecteur de vaccin à base de salmonelle (L-12259). Caption title. "December 2017." Issued also in print format. |
| Publishing information | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. : ill. |
| ISBN | 9780660239675 |
| Catalogue number |
|
| Subject terms | Drug delivery systems Salmonella |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: